IP Verse

Crystalline Forms Of An Androgen Receptor Modulator

Patent No. EP2858985 (titled "Crystalline Forms Of An Androgen Receptor Modulator") was filed by Aragon Pharmaceuticals on Jun 4, 2013. The application was issued on Apr 18, 2018.

Patent Summary

Anti-androgen drug that suppresses both AR nuclear translocation and AR binding to androgen response elements in DNA. The drug inhibits both AR nuclear translocation and AR binding to androgen response elements in DNA.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKJan 18, 2019TER MEER STEINMEISTER & PARTNER
LUIGIJan 18, 2019TER MEER STEINMEISTER & PARTNER
SAGITTARIUSJan 18, 2019SAGITTARIUS

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2858985

ARAGON PHARMACEUTICALS
Application Number
EP13800681A
Filing Date
Jun 4, 2013
Status
Opposition Rejected
Aug 2, 2024
Publication Date
Apr 18, 2018
External Links
Slate, Register , Google Patents